From the health system perspective, there needs to be improvement in treating HIV as a comprehensive disease that now goes into aging, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
From the health system perspective, there needs to be improvement in treating HIV as a comprehensive disease that now goes into aging, explained Stella A. Safo, MD, assistant professor of Medicine at the Icahn School of Medicine at Mount Sinai.
Transcript
With the advent of antiretroviral therapy, people living with HIV are living longer. With aging HIV populations, what challenges are there in treating patients with comorbidities, such as cancer?
I love my patient panel. I love seeing patients who, when they were in their early 20s and were diagnosed, thought they would be dead within years. Now they’re in their 50s and 60s and still going strong. One of the biggest challenges, I would say, comes from both a health system but also from the patients. From the health system perspective, I think we are still a little bit not so great about treating HIV as a comprehensive disease that now goes into aging.
From the patient perspective, I have patients who really believed they would be dead in a few years and so when you talk about things like other chronic disease management, like diabetes and smoking cessation, they have a feeling that their HIV is going to be the thing that impacts them anyway. So, there’s a little bit less of a sense of stopping some of the negative behaviors that have really been a problem for them. I think because of that, the behavioral change I do with some of these patients can be a little bit difficult.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More